Pancreatic Cancer Research

ResearcherKyoto UniversityActive in the last 2 years

Naoya Sasaki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2648-304X; OpenAlex author ID A5084405732, A5129663434. Sources: OpenAlex.

Their work

Papers
3
Trials
0
Grants
0
Labs led
0
Collaborators
12
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 3

  1. Prognostic Impact of Major Pathologic Response After Preoperative Treatment in Resected Pancreatic Ductal Adenocarcinoma: A Multi-Institutional Retrospective S… Co-author DOI 10.1097/sla.0000000000007052↗
  2. Neoadjuvant therapy with intensity-modulated radiotherapy combined with S-1 for borderline-resectable pancreatic cancer. Co-author DOI 10.1111/ajco.14080↗
  3. Alpha-fetoprotein-producing pancreatic cancer cells possess cancer stem cell characteristics. Co-author DOI 10.1016/j.canlet.2011.04.023↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yusuke Okamura · 2 shared papers, 2024–2026 · strength 0.41
  2. Dai Manaka · 1 shared paper, 2024 · strength 0.21
  3. Shintaro Yagi · 1 shared paper, 2026 · strength 0.21
  4. Asahi Sato · 1 shared paper, 2026 · strength 0.21
  5. Toshihiko Masui · 1 shared paper, 2026 · strength 0.21
  6. Yuichiro Uchida · 1 shared paper, 2026 · strength 0.21
  7. Masato Narita · 1 shared paper, 2026 · strength 0.21
  8. Kei Yamane · 1 shared paper, 2026 · strength 0.21
  9. Kazuyuki Nagai · 1 shared paper, 2026 · strength 0.21
  10. Etsuro Hatano · 1 shared paper, 2026 · strength 0.21
  11. Iwao Ikai · 1 shared paper, 2011 · strength 0.03
  12. Shinji Üemoto · 1 shared paper, 2011 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.